# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**WASHINGTON, D.C. 20549**

# FORM 8-K

**CURRENT REPORT**
**Pursuant to Section 13 or 15(d)**
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 30, 2023**

# Apellis Pharmaceuticals, Inc.
**(Exact Name of Registrant as Specified in its Charter)**

| **Delaware** | **001-38276** | **27-1537290** |
|---|---|---|
| **(State or Other Jurisdiction of Incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

| | |
|---|---|
| **100 Fifth Avenue**<br>**Waltham, MA**<br>**(Address of Principal Executive Offices)** | **02451**<br>**(Zip Code)** |

**Registrant's telephone number, including area code: (617) 977-5700**

**Not applicable**
**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock | APLS | Nasdaq Global Select Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD.**

On November 30, 2023, Apellis Pharmaceuticals, Inc. (the "Company") updated the U.S. Prescribing Information ("USPI") for SYFOVRE® (pegcetacoplan) for the treatment of geographic atrophy secondary to age-related macular degeneration. The "Warnings and Precautions and Adverse Reactions - Postmarketing Experience" sections of the USPI will now include information regarding the previously reported rare events of retinal vasculitis with or without occlusion in patients treated with SYFOVRE. The Company pursued this update in collaboration with the U.S. Food and Drug Administration.

The estimated rate of events of retinal vasculitis remains rare at 0.01% per injection, with more than 120,000 injections estimated to have been administered as of November 18, 2023.

The information in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Apellis Pharmaceuticals, Inc.**

Date: December 1, 2023

By: /s/ Timothy Sullivan
Timothy Sullivan
Chief Financial Officer